These findings suggested that the clinical efficacy of some antibodies is reduced by the occurrence of certain similar mutations; however, because E746_A750 and L858R somatic mutations account for >70% of EGFR mutations [19], screening NSCLC patients using the device described in the present study could potentially increase diagnostic speed and accuracy and identification of candidates for EGFR TKI therapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.